Bristol Myers Squibb Foundation: Robert A. Winn Diversity in Clinical Trials Award Program (early-career)

The Robert A. Winn Diversity in Clinical Trials Award Program was created to increase diversity in clinical trials and transform the clinical research landscape.

The program invites applications for the third cohort of the Robert A. Winn Diversity in Clinical Trials: Career Development Award (Winn CDA) program, which seeks to transform the clinical research landscape by building and strengthening partnerships between clinical investigators and the communities where their patients reside and to facilitate an approach to clinical and translational research that is community-informed, designed, and conducted. The program awards $120,000 annually for two years to support scholars mentored by an experienced clinical investigator at an established clinical trial site. Scholars must participate substantively in the mentor’s active clinical trial (it is not expected that scholars will have their own clinical trials). Clinical research focus areas include cancer (hematology and oncology), cardiovascular disease, and immunologic disorders.

For the Winn CDA program, the following racial/ethnic groups are designated as “underrepresented in medicine”: African American or Black, Hispanic/Latine, American Indian or Alaska Native, Native Hawaiian or Other Pacific Islander, or Southeast Asian; or have a demonstrated commitment to increasing diverse patient participation in clinical trials.

Candidates should be Early-Stage Investigators (ESIs), defined by NIH as new investigators who have completed their terminal research degrees or medical residencies—whichever date is later—within the past 10 years and have not yet competed successfully for substantial NIH research grants. (Applicants with an RO1 or RO1 equivalent are ineligible.)

To be eligible, candidates must hold the degree of MD, MD/PhD, DO or DO/PhD and be US Citizens or Lawful Permanent Residents (LPRs) as defined by the US Department of Homeland Security.